Have a feature idea you'd love to see implemented?
Let us know!
ZYXI Zynex Inc
Price (delayed)
$8.11
Market cap
$258.27M
P/E Ratio
57.93
Dividend/share
N/A
EPS
$0.14
Enterprise value
$294.91M
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery
Highlights
Zynex's revenue has increased by 4.2% YoY
The gross profit has grown by 3.8% YoY
The equity has declined by 39% year-on-year but it is up by 9% since the previous quarter
Zynex's net income has plunged by 70% YoY and by 20% from the previous quarter
The EPS has plunged by 67% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of ZYXI
Market
Valuations
Earnings
Shares outstanding
31.85M
Market cap
$258.27M
Enterprise value
$294.91M
Price to earnings (P/E)
57.93
Price to book (P/B)
7.2
Price to sales (P/S)
1.33
EV/EBIT
33.25
EV/EBITDA
22.72
EV/Sales
1.52
Revenue
$193.67M
EBIT
$8.87M
EBITDA
$12.98M
Free cash flow
$15.53M
Per share
Balance sheet
Liquidity
EPS
$0.14
Free cash flow per share
$0.49
Book value per share
$1.13
Revenue per share
$6.09
TBVPS
$3.09
Total assets
$126.06M
Total liabilities
$90.29M
Debt
$74.68M
Equity
$35.77M
Working capital
$58.48M
Debt to equity
2.09
Current ratio
3.94
Quick ratio
3
Net debt/EBITDA
2.82
Margins
Efficiency
Dividend
EBITDA margin
6.7%
Gross margin
79.5%
Net margin
2.5%
Operating margin
4.6%
Return on assets
3.8%
Return on equity
13.1%
Return on invested capital
7.5%
Return on capital employed
8.4%
Return on sales
4.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZYXI stock price
How has the Zynex stock price performed over time
Intraday
3.18%
1 week
0.25%
1 month
-3.11%
1 year
-9.28%
YTD
-25.53%
QTD
-0.61%
Financial performance
How have Zynex's revenue and profit performed over time
Revenue
$193.67M
Gross profit
$153.95M
Operating income
$8.85M
Net income
$4.82M
Gross margin
79.5%
Net margin
2.5%
The net margin has plunged by 71% YoY and by 19% from the previous quarter
Zynex's net income has plunged by 70% YoY and by 20% from the previous quarter
Zynex's operating margin has shrunk by 54% YoY and by 15% QoQ
The company's operating income has shrunk by 52% YoY and by 16% QoQ
Growth
What is Zynex's growth rate over time
Valuation
What is Zynex stock price valuation
P/E
57.93
P/B
7.2
P/S
1.33
EV/EBIT
33.25
EV/EBITDA
22.72
EV/Sales
1.52
The EPS has plunged by 67% YoY and by 18% from the previous quarter
The P/E is 33% above the 5-year quarterly average of 43.5 and 11% above the last 4 quarters average of 52.4
The equity has declined by 39% year-on-year but it is up by 9% since the previous quarter
The P/B is 21% less than the 5-year quarterly average of 9.1 and 21% less than the last 4 quarters average of 9.1
The price to sales (P/S) is 68% lower than the 5-year quarterly average of 4.1 and 26% lower than the last 4 quarters average of 1.8
Zynex's revenue has increased by 4.2% YoY
Efficiency
How efficient is Zynex business performance
ZYXI's ROA has dropped by 68% year-on-year and by 16% since the previous quarter
The ROIC has plunged by 65% YoY and by 11% from the previous quarter
The ROS has plunged by 60% YoY and by 13% from the previous quarter
ZYXI's ROE is down by 48% year-on-year and by 8% since the previous quarter
Dividends
What is ZYXI's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Zynex financials performed over time
The total assets is 40% more than the total liabilities
ZYXI's quick ratio is down by 31% YoY
ZYXI's current ratio is down by 24% YoY and by 3% from the previous quarter
The debt is 109% more than the equity
Zynex's debt to equity has soared by 61% YoY but it has decreased by 8% from the previous quarter
The equity has declined by 39% year-on-year but it is up by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.